← Eichor
Study identifier: NCT06736275 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

A Phase I Study on Evaluating the Safety, Tolerability, Pharmacokinetic Characteristics and Preliminary Efficacy of SXRN Plasmid DNA Technique in Patients With Advanced Solid Tumors

Condition: Advanced Cancer · Cachexia  ·  Sponsor: Jiangsu Nutai Biologics Co., Ltd

PhaseEARLY_Phase 1
Planned participants28
Who can joinAll sexes, 18 Years to 75 Years
Healthy volunteersNo

About this study

The purpose of this clinical trial is to evaluate the safety and tolerability of SXRN Plasmid DNA Technique in patients with advanced solid tumors.

This description comes directly from the study's public registry record.

Talk to the study team

Ning Li  ·  +86 10 8778 8713  ·  lining@cicams.ac.cn

Always discuss trial participation with your own doctor first.

Locations (1)

Cancer Hospital Chinese Academy of Medical SciencesBeijing, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06736275